OBTEC

Wipo Regional Workshop on Patent Analytics

WIPO & INPI

Rio de Janeiro, August 26 a 28, 2013

Samples of Patent Analytics

Observatory of Tecnologies - INPI/ Brazil

Prof. Adelaide Antunes

aantunes@inpi.ufrj.br

OBTEC

OBTEC / INPI

Created in 2010, the Observatory stimulates the interactionbetween Brazilian Office and the several stakeholders of the Brazilian National Innovation System (Universities, Research

Institutes, Finance Organizations, Government Agencies)

Created in 2010, the Observatory stimulates the interactionbetween Brazilian Office and the several stakeholders of the Brazilian National Innovation System (Universities, Research

Institutes, Finance Organizations, Government Agencies)

Observatory of Technologies

Strategic utilizationStrategic utilization of IP System in favor of of IP System in favor of

the economic development.the economic development.

Observatory of Technologies

Strategic utilizationStrategic utilization of IP System in favor of of IP System in favor of

the economic development.the economic development.

OBTEC

Wipo Regional Workshop on Patent Analytics

Observatory of Tecnologies - INPI/ Brazil

It´s necessary

to identify the needs

To develop a Strategy

To search for information

To analyse

To disseminate

Reports

(patents)

Reports

(patents)

University (papers)

INPI (Government)

Industries

Innovation

Economic Development

University (papers)

INPI (Government)

Industries

Innovation

Economic Development

OBTEC

Partnership INPI – OBTEC / FINEP

(Funding Authority for Studies and Projects)

Observatory in the Health Sector

COOPERATION AGREEMENTCOOPERATION AGREEMENT

FINEP –goal: Introduce IP Culture

Brands / Patents

FINEP –goal: Introduce IP Culture

Brands / Patents

OBTEC

EX.: EMSEX.: EMS

Trademarks

Company

Sector Trademarks (applications)

Pending applications

Registered trademarks

Dead trademarks

Frist Application

Latest Application

E M S Drugs 938 237 453 248 Nov., 1963 June, 2012

Priority Country

Patent Documents

Brazil 7Great Britain 3

Patent documents x Priority year

0

1

2

3

4

2003 2004 2005 2006 2007 2008 2009 2010 2011 priority year

pat

ent

do

cum

ents

Patents

Major Generic Drug Company (80% incoming)

Major Generic Drug Company (80% incoming)

OBTEC

STUDIES - DRUGS- FINEP STUDIES - DRUGS- FINEP

Grupo I - Tipo i Capítulo da NCM  Medicamentos a base dos fármacos

1 3004.90.68 Atazanavir2 3004.90.69 Ganciclovir3 3004.39.27 Gosserelina4 3004.90.99 Hidroxiuréia5 3004.90.68 Indinavir Sulfato6 3004.31.00 Insulina

7 3004.90.99Isoniazida/Rifampicina/Pirazinamida/

Etambutol8 3004.39.81 Levotiroxina9 3004.90.39 Mitoxantrona

10 3004.90.42 TalidomidaRegra de origem: salto de posição tarifária, exceto do

capítulo 30

OBTEC

GanciclovirGanciclovir

RN: 82410-32-0 IUPAC: 2-amino-1,9-dihydro-9-[[2-hydroxy-1-

(hydroxymethyl)ethoxy]methyl]-6H-Purin-6-one Therapeutic class: antiviral Names and brands 2-Amino-1,9-[[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl]6H-purin-6-one

Biolf 62

BN-B759V

Gansikloviiri

Gansiklovir

Gancyclovir

Gancyklovir

Ganecicilovir

Gansikloviiri

Gansiklovir

HSDB 6512

OBTEC

GanciclovirGanciclovir

Labs Brasil (DEF)

Roche Halex Istar Blausiegel Lafepe Eurofarma

Producers(DWCP) – 38

China - 24

Índia - 4

Alemanha - 3

Estados Unidos - 2

Argentina, Brasil, Canadá, França, Itália – 1

N º Priority documents / Country China - 18

EUA - 5Índia - 5

Escritório Europeu de Patentes - 2 (Itália e França)Espanha e a Itália - 1 depósito cada.

OBTEC

Partnership INPI – OBTEC / FIOCRUZ

Oswaldo Cruz Foundation Science at Service of Life

Observatory in the Health Sector

COOPERATION AGREEMENTCOOPERATION AGREEMENT

OBTEC

Partnership INPI (OBTEC) / FIOCRUZPartnership INPI (OBTEC) / FIOCRUZ

to identify global trends in cancer

subsidize decision-making processes in the Brazilian healthcare sector

Definition of (Brazilian) priorities

Important to know the Patent landscape on cancer drugs

not-patented technologies

patents that have expired

OBTEC

Manual Code Definição B14-H01P Multiple myeloma B14-H01R Oesophageal cancer B14-H01S Ovarian cancer B14-H01T Pancreatic cancer B14-H01U Prostate cancer B14-H01V Rectal cancer B14-H01W Skin melanoma B14-H01X Stomach cancer B14-H01Y Testicular cancer B14-H02 Mutagen, carcinogen B14-H03 Apoptotic B14-H04 Anti-apoptotic B14-H06 Radiosensitizers - Drugs to make tumour cells more

sensitive to radiation therapy B14-S11C Anticancer vaccine B04-G0500E anticancer cell B04-K01S0E cancer cell/cancer cell antigen receptor B04-F02A0E cancer cells, carcinoma (mammalian) B12-G07 Anticancer B04-E02G / B04-E03G

Oncogene

Partnership INPI (OBTEC) / FIOCRUZPartnership INPI (OBTEC) / FIOCRUZ

Manual Code Definição B04-B04C4 Anticancer antibody - B04-B04C8 Cancer antigen B04-F02A Cancer cells/Carcinoma B04-K01S Cancer cell or cancer cell antigen receptor B12-K04A1 Diagnosis of tumours, cancer B14-H01 Anticancer general and other B14-H01A Leukaemia treatment B14-H01B Antiproliferative, inhibitor of cell division, cytostatic B14-H01C Dermatological cancers B14-H01D Endocrine cancers B14-H01D1 Breast cancers B14-H01D2 / B14-H01Z

Thyroid cancers

B14-H01E Gastrointestinal cancers B14-H01E1. Colon cancers B14-H01E2 Oesophageal cancers B14-H01E3 Gall bladder cancers B14-H01E4 Intestinal cancers B14-H01E5 Hepatic cancers B14-H01E6 Pancreatic cancers B14-H01E7 Rectal cancers

Manual Code Definição B14-H01E8 Stomach cancers B14-H01F Genitourinary cancers B14-H01F1 Cervical/uterine cancers B14-H01F2 Kidney cancers B14-H01F3 Ovarian cancers B14-H01F4 Prostate cancers B14-H01F5 Testicular cancers B14-H01F6 Bladder cancers B14-H01G Immunological cancers B14-H01G1 linfoma de hodgkin B14-H01G2 / B14-H01Q

linfoma não-hodkin

B14-H01H Musculoskeletal cancers B14-H01H1 Osteocancers B14-H01H2 Sarcoma B14-H01J Neurological cancers B14-H01J1 Brain tumours B14-H01K Oral and respiratory cancers B14-H01K1 Buccal cavity and pharynx cancers B14-H01K2 Larynx cancers B14-H01K3 Lung cancers B14-H01L Other cancers B14-H01L1 Multiple myelomas B14-H01M Larynx cancer B14-H01N Lung cancer

84.351 patent documents related to cancer drugs

(worldwide)

Derwent Innovations Index

OBTEC

STUDIES

OBTEC

call for papers: International Journal of Molecular Sciences (2013)

Trends in Nanopharmaceutical Patents Trends in Nanopharmaceutical Patents

Case Study

Adelaide Antunes1, Iolanda Fierro1, Rafaela Guerrante1, Flavia Mendes2 and Maria Simone de M. Alencar3

1INPI; 2UFRJ ; 3FIOCRUZ

Scientific journalScientific journal

OBTEC

MethodologyMethodology

Data Base Derwent Innovations Index

Main Advantages

The summaries are full of keywords

The possibility of exporting the patent documents recovered in the search using software (Vantage Point)

The availability of Manual Code related to nanotechnology (classification attributed in the database to all patent documents indexed in it)

Selection of documents that were indexed between 2002 and 2012 in the Derwent database

OBTEC

Manual Codes related to nanotechnology applied to the Manual Codes related to nanotechnology applied to the pharmaceutical sector, and the number of patent documentspharmaceutical sector, and the number of patent documents

Derwent manual code Description Number of patent

documentsB12-M11Q Nanoparticles 2,306

B12-M10A7 Nanotechnology devices 160

B11-C12 Nanotechnology (general) 5,028

B05-U05A Nanotubes, nanorods or nanohorns

100B05-U05B nanofilms

B05-U05C Nanostructures, other than those covered by B05-U05A and B05-U05B

B05-U05 Other carbon containing 3-D structures 44

B05-U04 Carbon plus heteroatom nanotubes 40

B05-U03 Carbon-only nanotubes 615

Removing the patent document that were in more than one of the nine seriesRemoving the patent document that were in more than one of the nine series

toxicity and nanoparticle

nano-imaging agent

nanoparticle for drug delivery

cancer-targeting nanoparticle

Focus on Special Issue “Bioactive Nanoparticle 2012”

Focus on Special Issue “Bioactive Nanoparticle 2012”

OBTEC

ResultsResults

OBTEC

The main patent applicant by area

Total of patents

Entity applying for patents

Toxicity of nanoparticle

Nano-imaging

agent

Nanoparticle for drug delivery

Cancer-targeting

nanoparticle

23 Univ. of California 7 9 7 9

21 Massachusetts Inst. Technology 8 5 7 11

20 General Electric Co 10 20 0 0

16Univ. Nat. Tsing Hua

0 0 12 0

15 GP Medical Inc. 0 0 11 0

12 Univ. Texas System 0 6 5 6

8 Univ. Northwestern 0 0 0 6

8 Elan Pharma Int. Ltd 7 0 0 0

8 Konink Philips Electronics NV 0 8 0 0

7Centre National de La Recherche

Scientifique (CNRS)7 0 0 5

7 Abraxis Bioscience LLC 7 0 0 0

7 Fuji Film Co Ltd 0 0 6 0

6 Brigham & Women’s Hospital Inc. 0 0 0 6

5 Univ. Kyushu 0 0 5 0

OBTEC

MIT Partnerships Auto-Correlation Map

Assignee Codes & Names :empre...

Links >= 0.000000 shown> 0.75 1 (0)0.50 - 0.75 0 (0)0.25 - 0.50 2 (0)< 0.25 7 (0)

UNIV NORTHWESTERNUNIV NORTHWESTERN

UNIV CORNELLUNIV CORNELL

M ITM IT

IM M UNE DISEASE INSTIM M UNE DISEASE INST

HARVARD COLLEGEHARVARD COLLEGE

GEN HOSPITAL CORPGEN HOSPITAL CORP

CHILDRENS HOSPITAL BOSTONCHILDRENS HOSPITAL BOSTON

BRIGHAM &WOM ENS HOSPITAL INCBRIGHAM &WOM ENS HOSPITAL INC MIT

nanoparticles for use in encapsulating a biologically active agent (e.g., polynucleotide)

Advantage is in effectively providing low immunogenicity and toxicity

Universities and HospitalsUniversities and Hospitals

OBTEC

Chapter 5 - The Contribution of Information Science through Intellectual Property to Innovation in the Brazilian Health Sector

Adelaide Maria de Souza Antunes, Flavia Maria Lins Mendes, Suzanne de Oliveira Rodrigues Schumacher,

Luc Quoniam, Jorge Lima de Magalhães

Rethinking The Conceptual Base For New Practical Applications In The Information Value And Quality (IGI

Global 2014 USA)

Rethinking The Conceptual Base For New Practical Applications In The Information Value And Quality (IGI

Global 2014 USA)

OBTEC

Brazil Health System (SUS)

Section 1: Pharmaceuticals industry, made up of six groups

Group 1 – Antivirals (including antiretrovirals)

Group 2 – Neglected Diseases

Group 3 – Chronic non-communicable diseases

Group 4 – Biological pathways

Group 5 – Vaccines and Hemoderivatives

Group 6 – Medications and inputs for the treatment of medical issues resulting from nuclear accidents.

Section 2: Medical devices and healthcare devices in general

OBTEC

Methodology

Database used to access the patent documents: SciFinder Scholar

Search for each drug, using the CAS Registry Number

Informations

patents relating to processes (synthesis and/or formulation);

main Applicants (assignees)

top countries

information about the first patent for the drug, date and respective assignee

patents filed in Brazil

trends over time of patenting

OBTEC

AtorvastatinAtorvastatin

Atorvastatin (CAS RN: 134523-00-5)

114 process patents

84 are for its synthesis

26 for its formulation

4 for its synthesis and formulation

Companies with the most patents (eight each)

Teva Pharmaceuticals Industries

Warner-Lambert Company

First patent

1986 Warner-Lambert Company

Brazil (17 deposits)

Warner Lambert Company (five for synthesis and one for formulation)

Teva Pharmaceuticals Industries (one for formulation and one for synthesis)

Pfizer (synthesis)

0

2

4

6

8

10

12

14

16

18

1986 1989 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009

Num

ber o

f Pat

ents

Priority Year

Patent Applications Filed for Atorvastatin

OBTEC

Calcitonin Calcitonin

Calcitonin (CAS RN: 9007-12-9) 204 process patents

169 are for its synthesis 28 for its formulation 7 for its synthesis and formulation

Companies with the most patents Armour Pharmaceutical (USA) - 9

First patent 1968 Ciba Ltd (Switzerland)

Brazil (10 patents) 2 for synthesis by Institut Gustave Roussy (France),

0

2

4

6

8

10

12

14

Num

ber o

f Pat

ents

Priority Year

Patent Applications Filed for Calcitonin

OBTEC

III Academic Intelectual Property and Innovation III Academic Intelectual Property and Innovation Development Meeting ( III ENAPID - INPI 2010)Development Meeting ( III ENAPID - INPI 2010)

Key Structures on Synthesis of HIV drugsKey Structures on Synthesis of HIV drugs

Adelaide Maria de Souza Antunes1, Rodrigo José Ávila Cartaxo2, Flavia Maria Lins Mendes2

1INPI; 2UFRJ

Scientific journalScientific journal

OBTEC

Top Applicants: Merck & Co - 15 patentes

Bristol-Myers Squibb Co - 10 patentes

54% em PCT

Technology domination: EUA – 40%

China, Índia e Japan – 41%

19 HIV / SciFinder (CAS/ACS) Busca: RN

19 HIV / SciFinder (CAS/ACS) Busca: RN

OBTEC

Methodology – 19 HIVMethodology – 19 HIV

OBTEC

KEY Chemical Substances Analysis for HIVsKEY Chemical Substances Analysis for HIVs

5-METHYLURIDINE

Me

O

NNH O

O

OHR S

Zidovudine Estavudine

Bristol-Myers (US) and Ajinomoto (JP)

4 routes2 routes

Bristol-Myers, Ajinomoto, Japan Tobacco and China Pharmacy Univ

24 producers :16 China, 2 Canada, 2 USA, 1 Italy, 1 Korea, 1 Slovakia and 1 Rússia

Me

N3

O

NNH O

O

OHRS

S

OBTEC

Thesis

Luiz André Felizardo S. Schlittler (EQ/UFRJ)Advisers: Prof. Nei Pereira Jr./ Profa. Adelaide

Antunes(INPI)

Mapping technological knowlodge of ethanol 2º GenerationMapping technological knowlodge of ethanol 2º Generation

OBTEC

Genetic modification micro-organims

Others compounds production

Enzyme production

Enzymatic hydrolysis

Produção de etanol 2G

Midwest R. Inst.

Univ. Florida

Technological focus

Technological focus

OBTEC

Thesis

Maria Simone de Menezes Alencar (EQ/UFRJ)Adviser: Adelaide Maria de Souza Antunes (INPI)

Technological Foresight applied nanotechnology

Technological Foresight applied nanotechnology

OBTEC

THERMS (strategy)THERMS (strategy)

Base de dados: Derwent Innovation Index

Termos selecionados ESTRATÉGIA DE BUSCA FULLERENES (fullerene*) NANOBELTS ((nanobelt*) or (“nano belt*“)) NANOBIOLOGY ((nanobiolog*) or (“nano biolog*“))

NANOBIOTECHNOLOGY ((nanobiotechnolog*) or (“nano biotechnolog*“) or (bionanotechnolog*) or (“bio nanotechnolog*“))

NANOCATALYST ((nanocatalys*) or (“nano catalys*“)) NANOCOMPOSITE (nanocomposit* or (“nano composit*“)) NANOCORNS ((nanocorn* or “nano corn*“)) NANOCRYSTAL (nanocrystal* or (“nano crystal*“)) NANODROPLETS ((nanodroplet*) or (“nano droplet*“)) NANODRUGS ((nanodrug* or “nano drug“*)) NANOELECTRONICS (nanoelectr* or (“nano electr*“))

OBTEC

ResultsResults

Top countries

Evolução histórica dos países com maior número de depósitos de patentes

3322311343471

537713

268

11791984

997716165929584214

0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

EUA JAPÃO CHINA ALEMANHA CORÉIA

2002-2005

1999-2001

1994-1998

OBTEC

AnalysisAnalysis

Classes CIP n patentes Principais usos Posição na nanocadeia de valor

Dispositivos eletrônicos Nanointermediário Dispositivos semicondutores Nanointermediário

H01L–semiconductor devices; electric solid state devices not otherwise provided

2870 Células solares Nanoprodutos Nanotubos de carbono Nanomatéria prima Células combustíveis Nanoprodutos

C01B—non-metallic elements; compounds thereof

2716 Catalisadores Nanointermediário Cancer (tratamento, medicação) Nanoprodutos Cosmeticos Nanoprodutos

A61K—preparations for medical, dental, or toilet purposes

1863 Drogas Nanoprodutos Nanotubos de carbono Nanomatéria prima Dispositivos eletrônicos Nanointermediário

B82B—nano-structures; manufacture or treatment thereof chemistry

1615

Catalisadores Nanointermediário Catalisadores Nanointermediário Células combustíveis Nanoprodutos

B01J —chemical or physical processes, e.g., catalysis, colloid chemistry; their apparatus

1520 Nanotubos de carbono Nanomatéria prima Proteinas Nanomatéria prima Ácidos Nucleicos Nanomatéria prima

G01N—investigating or analyzing materials by determining their chemical or physical properties

1362 Anticorpos Nanomatéria prima Filmes Nanointermediário Revestimentos Nanointermediário

C08K—Use of inorganic or non-macromolecular organic substances as ingredients

1351 Adesivos Nanointermediário Filmes Nanointermediário Revestimentos Nanointermediário

C08L—compositions of macromolecular compounds

1134 Fibras Nanointermediário Field emission display Nanointermediário Nanotubos de carbono Nanomatéria prima

H01J —electric discharge tubes or discharge lamps

1128 Mostradores Nanointermediário

OBTEC

Patenting in The USPatenting in The US

NANOINTERMEDIATES:biosensores, dispositivos

fotovoltaicos e para armazenamento de memória

NANOPRODUCTUS: radiografia industrial, sistemas óticos e de

imagem

NANOPRODUCTUS : com aplicações em

computadores, filmes e automóveis

NANOPRODUCTUS dentais, adesivos e revestimentos dentais e

equipamentos ortodônticos.

CLUSTER 1

OBTEC

Estratégia de Inovação e Tecnologia em Sementes.

Thesis

Rafaela Guerrante (EQ/UFRJ)

advisers: Prof. Nei Pereira Jr. e Profa. Adelaide Maria de Souza Antunes

Innovation Strategy and Technology in SeedsInnovation Strategy and Technology in Seeds

AgricultureAgriculture

OBTEC

Case Study – Monsanto’s patents on GURT (genetic use Case Study – Monsanto’s patents on GURT (genetic use restriction technology)restriction technology)

GURT technology

colloquially known as terminator/traitor technology

causes second generation seeds to be sterile Terminator

the use of an external chemical inducer which turns "on or off" a plant's genetic traits (ex. sterility) Traitor

There are not specific keywords/IPCs to describe GURT technology

1224 Monsanto’s patent documents were retrieved, possibly related to GURT

In order to validate the results and analyze the technologies described in the patents retrieved, a methodology was developed.

OBTEC

“mediated metabolism” OR “inducible”

- “sterile” OR “sterility”

“mediated metabolism” OR

“inducible”

+ “sterile” OR

“sterility”

“sterility” AND/OR “sterile”

“sterility” OR “sterile” OR “mediated metabolism”

OR “inducible”

More Relevant

807 documents

Search Result

1224 documents

Less Relevant

416 documents

Terminator

779 documents

Relevantes

416 documentos

Terminator and Traitor

5 documents

Traitor

23 documents

Reading of CLAIMS and/or

DESCRIPTION

Reading of CLAIMS and/or

DESCRIPTION

Reading of TITLE and/or ABSTRACT

Methodology 1st stepMethodology 1st step

OBTEC

“resistance to”

“increased grain yield”

“increased growth rate”

Filter“sterile”) AND

756 documents

764 docs.

MA

Reading of CLAIMS and DESCRIPTION

DISCARD

“herbicide tolerance”

Filter using AND/OR

“pest resistance”

“tolerance to”

Reading of CLAIMS

and DESCRIPTION

- (“sterility” OR male

Terminator779 documents

9 documents

related to

LE-STERILITY 1 doc.

NOT RELATED

8 documents

765 documents 14 documents

NOT RELATED

DO NOT CONTAIN - (“sterility” OR “sterile”)

AND male

+

Methodology 2st stepMethodology 2st step

OBTEC

Patent and Publications Networks related to Dengue and HPV vaccines: its implications for

policy of innovation in health

Thesis

Priscila Rohem-Santos (IE/UFRJ)

Advisor: Claudia Inês Chamas

OBTEC

Survey design and data sources / AnalysisSurvey design and data sources / AnalysisThe methodology of analysis involves: The search strategy encompasses definition of :

keywords

IPC and Derwent Manual codes

database

I – Identification of Dengue and HPV vaccine patent applications and articles;

II – Creation of clusters according to various indicators such as applicant, priority number, validity (legal status);

III – Claims' analysis of the applications filed in Brazil.

IV – Social Network analysis (coauthorsip/ corinventorship)

OBTEC

Survey design and data sources / AnalysisSurvey design and data sources / Analysis

(3 databases for patents)(3 databases for articles)

Merge results of diferent databases Harmonization of names – ThesaurusEx.: merges/acquisition of pharamautical industries considering the

vaccine sector

(Aventis Pasteur + Pasteur Meriex Connaugth = Aventis Pasteur (Sanofi) + Panacea + Shanta = Sanofi Pasteur (Homma et al, 2011)

Removal of duplicates

Adjacency matrices – correlation of data

OBTEC

RESULTS: HPV articles and patents networksRESULTS: HPV articles and patents networks

BR

OBTEC

RESULTS: Dengue articles and patents RESULTS: Dengue articles and patents networksnetworks

BRFragility of brazilian researchers’ conection

OBTEC

ThanksThanks!!!!!!

Adelaide AntunesAdelaide Antunesaantunes@inpi.gov.braantunes@inpi.gov.br

Elaine ViannaElaine Viannaelainev@inpi.gov.brelainev@inpi.gov.brBernanrdoNunesBernanrdoNunes

bernardo.nunes@inpi.gov.brbernardo.nunes@inpi.gov.brCristina D’Urso Cristina D’Urso

cmendes@inpi.gov.brcmendes@inpi.gov.brPriscila RohemPriscila Rohem

prirohem@inpi.gov.brprirohem@inpi.gov.brRafaela GuerranteRafaela Guerranterafaela@inpi.gov.brrafaela@inpi.gov.br

obtec@inpi.gov.brobtec@inpi.gov.br